ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Clonal Neoantigen T Cells ATL001

Also written as “ATL001” and “ATL-001 (Ciclopirox oral solution)”.

Its studies are mostly in Porphyria, Erythropoietic · Carcinoma, Non-Small-Cell Lung · Melanoma, led by 2 companies.

Drug pageAutologous Clonal Neoantigen T Cells ATL001: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 4, 20193 company-led studies, 1 open or runningNext primary completion: May 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Achilles Therapeutics UKits history only20 open or runningphase 2since Feb 4, 2019Feb 4, 2019none ahead
Atlas Molecular Pharmaits history only11 open or runningphase 2since Jun 3, 2025Jun 3, 2025May 1, 2028phase 2 · NCT07024316

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 4, 2019First study: phase 2 study in MelanomaNew to Achilles Therapeutics UKAchilles Therapeutics UK · NCT03997474 · 13 enrolled · Spain, United Kingdom
  2. Jul 17, 2019Phase 2 study in Advanced Non Small Cell Lung CancerAchilles Therapeutics UK · NCT04032847 · 27 enrolled · United States, France, Germany and more
  3. Jun 3, 2025Atlas Molecular Pharma’s first study: phase 2 study in Porphyria, ErythropoieticNew to Atlas Molecular PharmaAtlas Molecular Pharma · NCT07024316 · 6 planned · United States

Ahead

  1. May 1, 2028Primary completion: phase 2 study in Porphyria, ErythropoieticAtlas Molecular Pharma · NCT07024316

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07024316Porphyria, Erythropoietic · United States2RecruitingAtlas Molecular PharmaMay 1, 20286
NCT04032847Advanced Non Small Cell Lung Cancer · United States, France, Germany and more2TerminatedAchilles Therapeutics UKSep 26, 202427
NCT03997474Melanoma · Spain, United Kingdom2TerminatedAchilles Therapeutics UKSep 3, 202413

How it is read

Names in the registry

  • “ATL001”, 2 entries
  • “ATL-001 (Ciclopirox oral solution)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.